NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Other Current Assets
Current assets not reported separately, such as prepaid expenses.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets remains negative
Q1 FY2026 other current assets was $0, compared with $0 a year earlier.
Context
- Other current assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Assets vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 other current assets of $0 is the 7th highest of the 9 companies compared; the peer median is $792.04K.
- Other current assets amounts to 0.0% of total assets for NRXP, versus a peer median of 2.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.53M | -17.1% | -24.0% | 6.5% | |
| Mar 2026 | $4.66M | +147.6% | +41.9% | 15.1% | |
| Mar 2026 | $4.24M | +20.1% | +86.3% | 1.3% | |
| Mar 2026 | $953K | +2547.2% | — | 1.5% | |
| Mar 2026 | $631.08K | — | — | 3.2% | |
| Mar 2026 | $88K | -95.7% | +33.1% | 0.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | -45.7% | 0.0% | |
| Mar 2026 | -$3.34T | -50317557.5% | — | 15275760.8% | |
| Peer median (excluding NRXP) | $792.04K | +1.5% | +33.1% | 2.4% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.